Stay updated on Pembrolizumab in Neuroendocrine Tumors Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The page has been updated to version 2.16.5, and the previous version 2.16.4 has been removed. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    1%
    Check dated 2025-07-04T04:14:00.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    1.0%
    Check dated 2025-06-19T20:07:52.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    35 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:27:15.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-29T06:14:13.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T18:13:22.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    The page has undergone significant changes, including the removal of detailed information about a research study on pembrolizumab for treating metastatic high-grade neuroendocrine tumors, while adding references to collaborators and a new version revision.
    Difference
    39%
    Check dated 2025-04-16T13:12:49.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Neuroendocrine Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.